FDA advisory panel unanimously votes to approve Moderna's mRNA flu vaccine after Trump appointee tried to block review
By
Beth Mole
Summary
FDA independent advisors voted 9-0 to recommend approval of Moderna's mRNA seasonal flu vaccine (mRNA-1010), despite a Trump appointee at the agency initially attempting to block the vaccine from even being reviewed. The VRBPAC committee reviewed data and presentations on the vaccine in an all-day meeting before reaching their unanimous decision.
Source
Hacker NewsFDA advisory panel unanimously votes to approve Moderna's mRNA flu vaccine after Trump appointee tried to block reviewarstechnica.comKey quotes
· 3 pulledIndependent advisors for the Food and Drug Administration on Friday voted 9–0 in support of approving Moderna's seasonal mRNA flu vaccine
a Trump appointee at the agency initially tried to block it from even being reviewed
members of the FDA's advisory committee—known as VRBPAC for Vaccines and Related Biological Products Advisory Committee—pored over data and presentations on the vaccine
You might also wanna read
FDA advisory panel endorses Moderna mRNA flu vaccine that was subject of controversy
statnews.com·4d ago
FDA advisory panel unanimously recommends Moderna's mRNA flu vaccine for older adults
A federal vaccine advisory panel (FDA's VRBPAC) unanimously voted to recommend approval of Moderna's mRNA influenza vaccine (mRNA-1010, bran
cidrap.umn.edu·3d ago
FDA advisory panel unanimously recommends Moderna's mRNA flu vaccine for older adults
An FDA advisory panel unanimously recommended approval of Moderna's mRNA-based flu vaccine, mFlusiva, for older adults. The vaccine uses the
bit.ly·4d ago
Moderna's combined flu and COVID-19 mRNA vaccine shows durable immune response in mid-stage trial
Moderna announced promising results from a mid-stage trial of its combined mRNA seasonal flu and COVID-19 vaccine (mRNA-1073). The study inv
cidrap.umn.edu·10d ago
Oxford and Moderna receive approval for Phase 1 trial of mRNA vaccine to prevent Lynch syndrome cancers
The INTERCEPT-Lynch trial, a Phase 1 study funded by Moderna and sponsored by the University of Oxford, has received regulatory approval fro
cancer.ox.ac.uk·14d agohttps://doi.org/10.1056/NEJMoa2516491
Comments
Sign in to join the conversation.
No comments yet. Be the first.